Predictive value of the <scp>CLL</scp>‐<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo‐immunotherapy as first‐line treatment
Massimo Gentile(Azienda Ospedaliera di Cosenza), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Ilaria Angeletti(Azienda Ospedaliera S.Maria), Robin Foà(Sapienza University of Rome), Giovanni Tripepi(National Research Council), F. Angrilli(University of Padua), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Yair Herishanu(Tel Aviv University), Angela Rago(Sapienza University of Rome), Francesca Romana Mauro(Sapienza University of Rome), Giovanni Del Poeta(University of Rome Tor Vergata), Parikh A. Sameer(Mayo Clinic), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Manlio Ferrarini(North Shore University Hospital), Tait D. Shanafelt(Mayo Clinic), Francesco Di Raimondo(University of Catania), Marta Coscia(University of Turin), Annalisa Chiarenza(University of Catania), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Antonino Neri(University of Milan), Idanna Innocenti(Università Cattolica del Sacro Cuore), Maria Ilaria Del Principe(University of Rome Tor Vergata), Annamaria Giordano(University of Bari Aldo Moro), Osnat Bairey(Tel Aviv University), Stefano Molica(Azienda Ospedaliera Pugliese Ciaccio), Anna Grazia Recchia(Azienda Ospedaliera di Cosenza), Stefania Ciolli(Azienda Ospedaliero-Universitaria Careggi), Katja Zirlik(University Medical Center Freiburg), Neta Goldschmidt(National Institutes of Health), Luca Laurenti(Fondazione Roma), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Ernesto Vigna(Ospedale Annunziata di Cosenza), Lev Shvidel(Kaplan Medical Center), Kari G. Chaffee(Mayo Clinic in Florida), Neil E. Kay(Mayo Clinic), Aaron Polliack(Hadassah Medical Center), Giovanna Cutrona(Ospedale Policlinico San Martino)
Cited by 12
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k